{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:44:09Z","timestamp":1777956249365,"version":"3.51.4"},"reference-count":119,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T00:00:00Z","timestamp":1573344000000},"content-version":"vor","delay-in-days":2261,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"name":"SONK","award":["CA75362"],"award-info":[{"award-number":["CA75362"]}]},{"name":"United States National Cancer Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1093\/annonc\/mdt303","type":"journal-article","created":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T04:56:37Z","timestamp":1375764997000},"page":"2206-2223","source":"Crossref","is-referenced-by-count":3040,"title":["Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013"],"prefix":"10.1016","volume":"24","author":[{"given":"A.","family":"Goldhirsch","sequence":"first","affiliation":[]},{"given":"E.P.","family":"Winer","sequence":"additional","affiliation":[]},{"given":"A.S.","family":"Coates","sequence":"additional","affiliation":[]},{"given":"R.D.","family":"Gelber","sequence":"additional","affiliation":[]},{"given":"M.","family":"Piccart-Gebhart","sequence":"additional","affiliation":[]},{"given":"B.","family":"Th\u00fcrlimann","sequence":"additional","affiliation":[]},{"given":"H.-J.","family":"Senn","sequence":"additional","affiliation":[]},{"given":"Kathy S.","family":"Albain","sequence":"additional","affiliation":[]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[]},{"given":"Jonas","family":"Bergh","sequence":"additional","affiliation":[]},{"given":"Herv\u00e9","family":"Bonnefoi","sequence":"additional","affiliation":[]},{"given":"Denisse","family":"Bretel-Morales","sequence":"additional","affiliation":[]},{"given":"Harold","family":"Burstein","sequence":"additional","affiliation":[]},{"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"Monica","family":"Castiglione-Gertsch","sequence":"additional","affiliation":[]},{"given":"Alan S.","family":"Coates","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Colleoni","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[]},{"given":"Nancy E.","family":"Davidson","sequence":"additional","affiliation":[]},{"given":"Angelo","family":"Di Leo","sequence":"additional","affiliation":[]},{"given":"Bent","family":"Ejlertsen","sequence":"additional","affiliation":[]},{"given":"John F.","family":"Forbes","sequence":"additional","affiliation":[]},{"given":"Richard D.","family":"Gelber","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Gnant","sequence":"additional","affiliation":[]},{"given":"Aron","family":"Goldhirsch","sequence":"additional","affiliation":[]},{"given":"Pamela","family":"Goodwin","sequence":"additional","affiliation":[]},{"given":"Paul E.","family":"Goss","sequence":"additional","affiliation":[]},{"given":"Jay R.","family":"Harris","sequence":"additional","affiliation":[]},{"given":"Daniel F.","family":"Hayes","sequence":"additional","affiliation":[]},{"given":"Clifford A.","family":"Hudis","sequence":"additional","affiliation":[]},{"given":"James N.","family":"Ingle","sequence":"additional","affiliation":[]},{"given":"Jacek","family":"Jassem","sequence":"additional","affiliation":[]},{"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[]},{"given":"Per","family":"Karlsson","sequence":"additional","affiliation":[]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[]},{"given":"Moise","family":"Namer","sequence":"additional","affiliation":[]},{"given":"C.","family":"Kent Osborne","sequence":"additional","affiliation":[]},{"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[]},{"given":"Fr\u00e9d\u00e9rique","family":"Penault-Llorca","sequence":"additional","affiliation":[]},{"given":"Charles M.","family":"Perou","sequence":"additional","affiliation":[]},{"given":"Martine J.","family":"Piccart-Gebhart","sequence":"additional","affiliation":[]},{"given":"Kathleen I.","family":"Pritchard","sequence":"additional","affiliation":[]},{"given":"Emiel J.T.","family":"Rutgers","sequence":"additional","affiliation":[]},{"given":"Felix","family":"Sedlmayer","sequence":"additional","affiliation":[]},{"given":"Vladimir","family":"Semiglazov","sequence":"additional","affiliation":[]},{"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[]},{"given":"Ian","family":"Smith","sequence":"additional","affiliation":[]},{"given":"Beat","family":"Th\u00fcrlimann","sequence":"additional","affiliation":[]},{"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[]},{"given":"Andrew","family":"Tutt","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[]},{"given":"Toru","family":"Watanabe","sequence":"additional","affiliation":[]},{"given":"Nicholas","family":"Wilcken","sequence":"additional","affiliation":[]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[]},{"given":"William C.","family":"Wood","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt303_bb0010","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"The Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdt303_bb0020","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.steroids.2011.02.025","article-title":"Association between breast cancer subtypes and response to neoadjuvant anastrozole","volume":"76","author":"Dunbier","year":"2011","journal-title":"Steroids"},{"key":"10.1093\/annonc\/mdt303_bb0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature11143","article-title":"Whole-genome analysis informs breast cancer response to aromatase inhibition","volume":"486","author":"Ellis","year":"2012","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdt303_bb0030","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10549-011-1486-2","article-title":"Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?","volume":"131","author":"Galimberti","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdt303_bb0035","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/SLA.0b013e31827660a8","article-title":"Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial","volume":"256","author":"Martelli","year":"2012","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mdt303_bb0040","doi-asserted-by":"crossref","unstructured":"A Goldhirsch RD Gelber MJ Piccart-Gebhart. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialThe Lancet 2013 July 18 [epub ahead of print] doi: 10.1016\/S0140-6736(13)61094-6","DOI":"10.1016\/S0140-6736(13)61094-6"},{"key":"10.1093\/annonc\/mdt303_bb0045","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(13)70225-0","article-title":"6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0050","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt303_bb0055","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausalhormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0060","first-page":"S2","article-title":"Overcoming resistance to endocrine therapy due to PI3K\/AKT pathway activation by combinations of mTOR, AKT or MEK inhibitors","volume":"22","author":"Osborne","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0065","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K Inhibition impairs BRCA1\/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdt303_bb0070","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdt303_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/284584","article-title":"TP53 status and response to treatment in breast cancers","author":"Varna","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1093\/annonc\/mdt303_bb0080","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccr.2012.04.027","article-title":"p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer","volume":"21","author":"Jackson","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdt303_bb0085","doi-asserted-by":"crossref","first-page":"18060","DOI":"10.1073\/pnas.1018858109","article-title":"Estrogen receptor prevents p53-dependent apoptosis in breast cancer","volume":"109","author":"Bailey","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdt303_bb0090","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1470-2045(11)70094-8","article-title":"TP53 Status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994\/BIG 1\u201300): a randomised phase 3 trial","volume":"12","author":"Bonnefoi","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0095","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials","volume":"379","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2012","journal-title":"Lancet"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0100","first-page":"S2","article-title":"The continued evidence from overviews: what is the clinical utility?","volume":"22","author":"Di Leo","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/2159-8290.CD-12-0462","article-title":"The genomic landscape of breast cancer as a therapeutic roadmap","volume":"3","author":"Ellis","year":"2013","journal-title":"Cancer Discov"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0110","first-page":"S3","article-title":"From the genome to bedside: are we lost in translation?","volume":"22","author":"Hayes","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0115","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0120","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","article-title":"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer","volume":"101","author":"Cheang","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt303_bb0125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","article-title":"Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer","volume":"31","author":"Prat","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0130","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt303_bb0135","doi-asserted-by":"crossref","unstructured":"TO Nielsen M-YC Polley SCY Leung. An international Ki-67 reproducibility study. Presented at the 35th San Antonio Breast Cancer SymposiumDecember 4\u20138, 2012Abstr S4\u20136","DOI":"10.1158\/0008-5472.SABCS12-S4-6"},{"key":"10.1093\/annonc\/mdt303_bb0140","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10549-011-1837-z","article-title":"Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review","volume":"132","author":"Luporsi","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdt303_bb0145","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1002\/ijc.27958","article-title":"Adherence to the Mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study","volume":"132","author":"Buckland","year":"2013","journal-title":"Int J Cancer"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0150","first-page":"S5","article-title":"Nutrition and physical activity influence on breast cancer incidence and recurrence","volume":"22","author":"Chlebowski","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0155","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.2012.42.0273","article-title":"Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer","volume":"30","author":"Folkerd","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0160","first-page":"S5","article-title":"Sex hormones and breast cancer risk and prognosis","volume":"22","author":"Dowsett","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0165","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdt303_bb0170","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10549-012-2073-x","article-title":"Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis","volume":"134","author":"Niraula","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdt303_bb0175","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","article-title":"Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial","volume":"28","author":"Sestak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0180","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2011.40.8666","article-title":"Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1\u201398 trial","volume":"30","author":"Ewertz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0185","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1200\/JCO.2010.29.5113","article-title":"Obesity and hormone therapy in breast cancer: an unfinished puzzle","volume":"28","author":"Goodwin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0190","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2010.33.2585","article-title":"Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial","volume":"29","author":"Pfeiler","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0195","first-page":"S6","article-title":"Adipose tissue and breast cancer progression: a link between metabolism and cancer","volume":"22","author":"Bertolini","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0200","first-page":"209","article-title":"Adipose tissue cells, lipotransfer and cancer: a challenge for scientists, oncologists and surgeons","volume":"1826","author":"Bertolini","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1093\/annonc\/mdt303_bb0205","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdr158","article-title":"Locoregional recurrence risk after lipofilling in breast cancer patients","volume":"23","author":"Petit","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0210","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nm.2379","article-title":"Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs","volume":"17","author":"Oskarsson","year":"2011","journal-title":"Nat Med"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0215","first-page":"S7","article-title":"Extracellular matrix players in breast cancer progression and metastasis","volume":"22","author":"Oskarsson","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0220","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt303_bb0225","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0230","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncology"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0235","first-page":"S1","article-title":"Personalized adjuvant therapies: lessons from the past","volume":"22","author":"Goldhirsch","year":"2013","journal-title":"The Breast"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0240","first-page":"S7","article-title":"Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastasis","volume":"22","author":"Kerbel","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0245","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2011.38.5740","article-title":"Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer","volume":"30","author":"Hassett","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0250","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ijc.28082","article-title":"A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study","volume":"131","author":"Drukker","year":"2013","journal-title":"Int J Cancer"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0255","first-page":"S9","article-title":"Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer","volume":"22","author":"Pusztai","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0260","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","article-title":"A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer","volume":"16","author":"Nielsen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt303_bb0265","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mds334","article-title":"Endopredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer","volume":"24","author":"Dubsky","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0270","doi-asserted-by":"crossref","unstructured":"DS groi I Sestak J Cuzick. Comparative performance of breast cancer index (BCI) versus oncotype DX and IHC4 in the prediction of late recurrence in hormonal receptor-positive lymph node negative breast cancer patients: a transATAC study. Presented at the 35th San Antonio Breast Cancer Symposium, December 4\u20138, 2012 (Abstr S1\u20139).","DOI":"10.1158\/0008-5472.SABCS12-S1-9"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0275","first-page":"S9","article-title":"Characterization and clinical impact of residual disease after neoadjuvant chemotherapy","volume":"22","author":"Viale","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0280","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0285","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02\u201398","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0290","first-page":"S10","article-title":"Risk stratification for treatment choice: opportunities, challenges and tools","volume":"22","author":"Andre","year":"2013","journal-title":"The Breast"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0295","first-page":"S11","article-title":"Immune signatures: prognostic and predictive role in breast cancer","volume":"22","author":"Sotiriou","year":"2013","journal-title":"The Breast"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0300","first-page":"S10","article-title":"Developing an effective breast cancer vaccine","volume":"22","author":"Curigliano","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0305","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0310","first-page":"S12","article-title":"Personalizing extent of breast cancer surgery according to molecular subtypes","volume":"22","author":"Morrow","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0315","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/cncr.26484","article-title":"Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer","volume":"118","author":"Kiess","year":"2012","journal-title":"Cancer"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0320","first-page":"S13","article-title":"Who should not undergo breast conservation?","volume":"22","author":"Rutgers","year":"2013","journal-title":"The Breast"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0325","first-page":"S13","article-title":"Close\/positive margins after breast-conserving therapy","volume":"22","author":"Wood","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0330","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","article-title":"Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial","volume":"14","author":"Galimberti","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0335","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt303_bb0340","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.breast.2012.06.013","article-title":"Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: sentinel node versus observation after axillary UltraSouND)","volume":"21","author":"Gentilini","year":"2012","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdt303_bb0345","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt303_bb0350","doi-asserted-by":"crossref","unstructured":"JR Yarnold. The UK START (standardisation of breast radiotherapy) trials: 10-year follow-up results. Presented at the 35th San Antonio Breast Cancer Symposium, December 4\u20138, 2012 (Abstr. S4\u20131).","DOI":"10.1158\/0008-5472.SABCS12-S4-1"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0355","first-page":"S14","article-title":"Hypofractionation in the era of modulated radiotherapy","volume":"22","author":"Harris","year":"2013","journal-title":"The Breast"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0360","first-page":"S14","article-title":"Partial breast irradiation: targeting volume or breast molecular subtypes?","volume":"22","author":"Orecchia","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0365","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ijrobp.2009.02.031","article-title":"Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO)","volume":"74","author":"Smith","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdt303_bb0370","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.radonc.2010.01.014","volume":"94","author":"Polgar","year":"2010","journal-title":"Radiother Oncol"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0375","first-page":"S15","article-title":"Partial breast re-irradiation for local recurrence of breast carcinoma: benefit and potential long term side effects","volume":"22","author":"Sedlmayer","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0380","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0385","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0390","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1158\/1078-0432.CCR-11-2956","article-title":"Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial","volume":"18","author":"Cheang","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0395","first-page":"S16","article-title":"Patients with triple-negative breast cancer: is there an optimal adjuvant treatment?","volume":"22","author":"Burstein","year":"2013","journal-title":"The Breast"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0400","first-page":"S17","article-title":"Extended adjuvant chemotherapy in endocrine non-responsive disease","volume":"22","author":"Colleoni","year":"2013","journal-title":"The Breast"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0405","first-page":"S16","article-title":"Selecting the neoadjuvant treatment by molecular subtype: how to maximise the benefit","volume":"22","author":"von Minckwitz","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0410","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1200\/JCO.2005.02.0818","article-title":"Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer","volume":"23","author":"Gianni","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0415","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10549-009-0333-1","article-title":"The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer","volume":"119","author":"Straver","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0420","first-page":"S16","article-title":"Patients with HER2 positive breast cancer: delivery, duration and combination therapies","volume":"22","author":"Piccart","year":"2013","journal-title":"The Breast"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0425","first-page":"S18","article-title":"Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer","volume":"22","author":"Davidson","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0430","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt303_bb0435","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/annonc\/mds330","article-title":"Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole","volume":"24","author":"Goss","year":"2013","journal-title":"Ann Oncol"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0440","first-page":"S19","article-title":"Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors","volume":"22","author":"Ingle","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0445","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt303_bb0450","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/jnci\/djs264","article-title":"Age-specific incidence of breast cancer subtypes: understanding the black-white crossover","volume":"104","author":"Clarke","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt303_bb0455","doi-asserted-by":"crossref","unstructured":"S Loibl C Jackisch S Gade. Neoadjuvant chemotherapy in the very young, 35 years of age or younger. Presented at the 35th San Antonio Breast Cancer Symposium, December 4\u20138, 2012 (Abstr. S3\u20131).","DOI":"10.1158\/0008-5472.SABCS12-S3-1"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0460","first-page":"S18","article-title":"Management of breast cancer in the very young","volume":"22","author":"Partridge","year":"2013","journal-title":"The Breast"},{"issue":"Supp 1","key":"10.1093\/annonc\/mdt303_bb0465","first-page":"S17","article-title":"Follow-up tests to detect recurrent disease: patient's reassurance or medical need?","volume":"22","author":"Smith","year":"2013","journal-title":"The Breast"},{"key":"10.1093\/annonc\/mdt303_bb0470","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1200\/JCO.2011.38.4529","article-title":"Targeting adjuvant chemotherapy: a good idea that needs to be proven!","volume":"30","author":"Hayes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0475","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.2011.37.7879","article-title":"Is adjuvant chemotherapy useful for women with luminal A breast cancer?","volume":"30","author":"Coates","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0480","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/annonc\/mds080","article-title":"Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen","volume":"23","author":"Prat","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0485","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/annonc\/mdn037","article-title":"Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?","volume":"19","author":"Regan","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0490","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/bcr2124","article-title":"Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures","volume":"10","author":"Wirapati","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdt303_bb0495","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/gim.2012.119","article-title":"Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer","volume":"15","author":"Reed","year":"2013","journal-title":"Genet Med"},{"key":"10.1093\/annonc\/mdt303_bb0500","first-page":"455","article-title":"Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer","volume":"17","author":"Vanderlaan","year":"2011","journal-title":"Am J Manag Care"},{"key":"10.1093\/annonc\/mdt303_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2013.03.009","article-title":"A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene recurrence score(R) assay in oestrogen receptor positive node negative breast cancer","author":"Davidson","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt303_bb0510","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/1471-2407-12-447","article-title":"Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer","volume":"12","author":"Hannouf","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdt303_bb0515","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10549-012-1989-5","article-title":"Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer","volume":"133","author":"Lamond","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdt303_bb0520","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1634\/theoncologist.2009-0275","article-title":"Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer","volume":"15","author":"Tsoi","year":"2010","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdt303_bb0525","first-page":"313","article-title":"Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer","volume":"11","author":"Hornberger","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1093\/annonc\/mdt303_bb0530","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1524-4733.2010.00724.x","article-title":"Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization","volume":"13","author":"Klang","year":"2010","journal-title":"Value Health"},{"key":"10.1093\/annonc\/mdt303_bb0535","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jnci\/djr484","article-title":"Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer","volume":"104","author":"Hall","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt303_bb0540","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3111\/13696998.2012.722572","article-title":"Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting","volume":"16","author":"Blohmer","year":"2013","journal-title":"J Med Econ"},{"key":"10.1093\/annonc\/mdt303_bb0545","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mds512","article-title":"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use","volume":"24","author":"Eiermann","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0550","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10549-012-1979-7","article-title":"Economic evaluation of the 70-gene prognosis-signature (MammaPrint(R)) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan","volume":"133","author":"Kondo","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdt303_bb0555","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/1097-0142(19910801)68:3<549::AID-CNCR2820680318>3.0.CO;2-J","article-title":"Ki-67 immunostaining in node-negative stage I\/II breast carcinoma: significant correlation with prognosis","volume":"68","author":"Sahin","year":"1991","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt303_bb0560","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/02841869709001282","article-title":"Ki-67, p53, ER-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer","volume":"36","author":"Railo","year":"1997","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0565","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/bjc.1998.515","article-title":"MIB-1 labelling index is an independent prognostic marker in primary breast cancer","volume":"78","author":"Jansen","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt303_bb0570","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00000658-200201000-00003","article-title":"Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years","volume":"235","author":"Mirza","year":"2002","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mdt303_bb0575","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/cncr.11188","article-title":"Ki-67 expression in breast carcinoma","volume":"97","author":"Trihia","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt303_bb0580","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/sj.bjc.6603756","article-title":"Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients","volume":"96","author":"de Azambuja","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt303_bb0585","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jnci\/djk020","article-title":"Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer","volume":"99","author":"Dowsett","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt303_bb0590","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jnci\/djm289","article-title":"Value of Ki-67 in two randomized trials of adjuvant chemo-endocrine therapies for node-negative breast cancer","volume":"100","author":"Viale","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt303_bb0595","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.2008.17.0829","article-title":"Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group trial 1\u201398 comparing adjuvant tamoxifen with letrozole","volume":"26","author":"Viale","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt303_bb0600","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa0810266","article-title":"Adjuvant chemotherapy in older women with early stage breast cancer","volume":"360","author":"Muss","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419369649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419369649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/9\/2206\/13790256\/mdt303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T18:08:09Z","timestamp":1688407689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419369649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":119,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0923753419369649"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt303","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}